Multidimensional drug profiling by automated microscopy

Science

Volumn 306, Issue 5699, 2004, Pages 1194-1198

  Perlman, Zachary E ^a   Slack, Michael D ^b,c   Feng, Yan ^a,d   Mitchison, Timothy J ^a   Wu, Lani F ^b   Altschuler, Steven J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c ALPHATECH Inc   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; TITRATION; TOXICITY;

AUTOMATED MICROSCOPY; HUMAN CELL CULTURE; TITRATION-INVARIANT SIMILARITY SCORE (TISS);

DRUG DOSAGE;

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ALPHA AMANITIN; ALSTERPAULLONE; ANISOMYCIN; APHIDICOLIN; APICIDIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAMPTOTHECIN; COLCHICINE; CYTOCHALASIN B; DACTINOMYCIN; DEXAMETHASONE; DIDEMNIN B; DOXORUBICIN; EMETINE; EMODIN; ETOPOSIDE; HYDROXYUREA; METHOTREXATE; NOCODAZOLE; OKADAIC ACID; OLOMOUCINE; OXAMFLATIN; PODOPHYLLOTOXIN; PUROMYCIN; PURVALANOL A; ROSCOVITINE; TUNICAMYCIN; UNINDEXED DRUG;

MEDICINE;

ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG IDENTIFICATION; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MULTIVARIATE ANALYSIS; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TITRIMETRY;

AUTOMATION; CELL CYCLE; CLUSTER ANALYSIS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FLUORESCENT DYES; HELA CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, FLUORESCENCE; PHARMACOLOGY; PHENOTYPE; STATISTICS; TOXICITY TESTS;

EID: 8444223104     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1100709     Document Type: Article

References (32)

1. M. B. Eisen, P. T. Spellman, P. O. Brown, D. Botstein, Proc. Natl. Acad. Sci. U.S.A. 95, 14863 (1998).
2. A. C. Gavin et al., Nature 415, 141 (2002).
3. Y. Ho et al., Nature 415, 180 (2002).
4. P. Uetz et al., Nature 403, 623 (2000).
5. R. F. Murphy, M. Velliste, G. Porreca, J. VLSI Signal Process. 35, 311 (2003).
6. J. H. Price et al., J. Cell. Biochem. Suppl. 39, 194 (2002).
7. W. K. Huh et al., Nature 425, 686 (2003).
8. T. L. Saito et al., Nucleic Adds Res. 32, D319 (2004).
9. C. Conrad et al., Genome Res. 14, 1130 (2004).
10. J. C. Hardman, L. E. Limbird, A. G. Gilman, Eds., The Pharmacological Basis of Therapeutics (McGraw-Hill, New York, ed. 10, 2001), pp. 39-42.
11. M. J. Marton et al., Nature Med. 4, 1293 (1998).
12. J. N. Weinstein et al., Science 275, 343 (1997).
13. K. D. Paull, C. M. Lin, L. Malspeis, E. Hamel, Cancer Res. 52, 3892 (1992).
14. U. Scherf et al., Nature Genet. 24, 236 (2000).
15. E. C. Gunther, D. J. Stone, R. W. Gerwien, P. Bento, M. P. Heyes, Proc. Natl. Acad. Sci. U.S.A. 100, 9608 (2003).
16. D. Leung, C. Hardouin, D. L. Boger, B. F. Cravatt, Nature Biotechnol. 21, 687 (2003).
17. M. A. Lindsay, Nature Rev. Drug Discov. 2, 831 (2003).
18. P. Y. Lum et al., Cell 116, 121 (2004).
19. G. Giaever et al., Proc. Natl. Acad. Sci. U.S.A. 101, 793 (2004).
20. S. J. Haggarty, P. A. Clemons, S. L. Schreiber, J. Am. Chem. Soc. 125, 10S43 (2003).
21. D. E. Root, S. F. Flaherty, B. P. Kelley, B. R. Stockwell, Chem. Biol. 10, 881 (2003).
22. V. C. Abraham, D. L. Taylor, J. R. Haskins, Trends Biotechnol. 22, 15 (2004).
23. M. D. Vera, M. M. Joullie, Med. Res. Rev. 22, 102 (2002).
24. C. J. Thomas, N. J. Rahier, S. M. Hecht, Bioorg. Med. Chem. 12, 1585 (2004).
25. Z. E. Perlman et al., data not shown.
26. C. M. Field, B. M. Alberts, J. Cell Biol. 131, 165 (1995).
27. M. Yoshida et al., Cancer Chemother. Pharmacol. 48 (suppl. 1), S20 (2001).
28. M. E. Noble, J. A. Endicott, L. N. Johnson, Science 303, 1800 (2004).
29. J. D. Laskin, D. E. Heck, D. L. Laskin, Toxicol. Sci. 69, 289 (2002).
30. B. Kaina, Biochem. Pharmacol. 66, 1547 (2003).
31. G. Lahav et al., Nature Genet. 36, 147 (2004).
32. We thank A. Daneau, M. Ethier, and B. Mantenuto at the Bauer Center for Genomics Research for their assistance with the use of the Bauer Center computational cluster and K. Maciag, A. Murray, O. Rando, A. Salic, and A. Yonetani for helpful discussions. Supported in part by National Cancer Institute PO1 CA078048. Z.E.P. is a Howard Hughes Medical Institute Predoctoral Fellow.